Antibody-Drug Conjugates (ADCs): Design, Development, and Clinical Impact

Introduction

Antibody-drug conjugates (ADCs) represent one of the most innovative and rapidly evolving classes of cancer therapeutics. These complex molecules combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, creating targeted therapies that deliver cell-killing payloads directly to cancer cells while sparing healthy tissues. The concept is elegant: an antibody seeks out and binds to a tumor-specific antigen, the conjugate is internalized, and the cytotoxic payload is released inside the cell to induce cell death.

The first ADC, gemtuzumab ozogamicin (Mylotarg), was approved by the FDA in 2000 for acute myeloid leukemia. However, early ADCs faced significant challenges related to toxicity and efficacy. It was not until the approvals of ado-trastuzumab emtansine (Kadcyla) in 2013 and brentuximab vedotin (Adcetris) in 2011 that the field gained real momentum. Today, over a dozen ADCs have received regulatory approval, and hundreds more are in clinical development. This article explores the design principles, development challenges, approved products, and future directions of ADC therapeutics. For detailed information on approved ADCs, the CodeDrug database provides comprehensive drug data.

Architecture of an ADC

An ADC consists of three essential components:

1. Antibody: Provides target specificity and determines the pharmacokinetic properties
2. Linker: Connects the antibody to the payload and controls payload release
3. Payload (cytotoxic drug): Provides the therapeutic effect

The optimization of each component—and critically, their integration—determines the overall efficacy and safety profile of the ADC.

The Antibody Component

Target Selection

The choice of target antigen is perhaps the most critical decision in ADC design. Ideal target antigens should possess:

• Tumor-specific expression: High expression on tumor cells with minimal expression on healthy tissues to reduce off-target toxicity
• Homogeneous expression: Uniform expression across the tumor to ensure all cancer cells are targeted
• Internalization capacity: Efficient internalization upon antibody binding to deliver the payload intracellularly
• No shedding: The antigen should not be shed into circulation, which could sequester the ADC before it reaches the tumor

Common ADC targets include HER2, CD30, CD33, CD22, TROP-2, Nectin-4, and folate receptor alpha.

Antibody Engineering

Most approved ADCs use IgG1 antibodies, which offer:

• Long serum half-life (approximately 21 days) through FcRn recycling
• Robust binding affinity (nanomolar to picomolar range)
• Immune effector functions (antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity)
• Well-established manufacturing processes

Antibody engineering advances have improved ADC performance:

• Humanized and fully human antibodies: Reduced immunogenicity compared to murine or chimeric antibodies
• Affinity tuning: Optimizing binding strength to balance tumor penetration and retention
• Fc engineering: Modifying Fc effector functions to reduce off-target toxicity or enhance immune engagement

The Linker

The linker is the critical bridge between antibody and payload, and its design profoundly influences ADC stability, pharmacokinetics, and therapeutic index. Linkers must be stable in circulation (to prevent premature payload release and systemic toxicity) but efficiently release the payload upon reaching the target cell.

Cleavable Linkers

Cleavable linkers exploit the biochemical differences between circulation and intracellular environments:

• Acid-labile linkers (hydrazones): Exploit the acidic environment of endosomes/lysosomes (pH 4.0–5.0) for payload release
• Protease-cleavable linkers (dipeptide linkers): Cleaved by lysosomal proteases such as cathepsin B; valine-citrulline (Val-Cit) is the most widely used
• Glutathione-sensitive linkers (disulfide bonds): Exploit the higher intracellular glutathione concentration to trigger reduction and payload release
• β-Glucuronide linkers: Cleaved by β-glucuronidase, an enzyme highly expressed in lysosomes and the tumor microenvironment

Non-Cleavable Linkers

Non-cleavable linkers (e.g., thioether bonds, maleimidocaproyl) remain intact during internalization. Payload release requires complete antibody degradation in lysosomes, releasing the payload still attached to a linker-amino acid fragment. This approach offers:

• Greater stability in circulation (reduced systemic toxicity)
• More controlled payload release
• Potentially broader therapeutic window

However, non-cleavable linkers limit the “bystander effect”—the ability of released payload to kill neighboring antigen-negative tumor cells—because the charged linker-amino acid-payload conjugate cannot cross cell membranes.

The Payload

Payload Requirements

ADC payloads must meet stringent criteria:

• High potency: Because only a small fraction of administered ADC reaches the tumor (typically 0.1–1% of injected dose per gram of tumor), payloads must be extremely potent (IC50 in the sub-nanomolar range)
• Appropriate hydrophobicity: Sufficiently hydrophobic to cross cell membranes for bystander effect, but not so hydrophobic as to cause aggregation or accelerate plasma clearance
• Stability: Must remain stable during circulation and storage
• Suitable linker conjugation sites: Must possess functional groups for linker attachment without loss of activity

Payload Classes

Payload Class	Mechanism	Examples	DAR Range
Microtubule inhibitors	Disrupt microtubule dynamics, causing cell cycle arrest	Auristatins (MMAE, MMAF), maytansinoids (DM1, DM4)	2–4
DNA-damaging agents	Create double-strand breaks or crosslinks in DNA	Calicheamicins, duocarmycins, PBD dimers	2–4
Topoisomerase inhibitors	Inhibit topoisomerase I, causing DNA damage	SN-38, DXd (deruxtecan)	4–8
RNA polymerase inhibitors	Inhibit transcription	α-Amanitin	2
Immune modulators	Modulate immune response rather than direct cytotoxicity	TLR agonists, STING agonists	Variable

Drug-to-Antibody Ratio (DAR)

The drug-to-antibody ratio—the average number of payload molecules per antibody—is a critical design parameter:

• Low DAR (2–4): Traditional range; balances potency with favorable pharmacokinetics
• High DAR (6–8): Can increase potency but may increase hydrophobicity, accelerate clearance, and increase toxicity
• DAR optimization: Newer conjugation technologies enable precise DAR control, with some platforms favoring homogeneous DAR distributions

Conjugation Technologies

Conventional Conjugation

Early ADCs used non-site-specific conjugation:

• Lysine conjugation: Random conjugation to surface lysine residues, producing heterogeneous mixtures (DAR 0–8)
• Cysteine conjugation: Partial reduction of interchain disulfide bonds, creating conjugates with DAR 0–8

These approaches produce heterogeneous products with variable pharmacokinetics and efficacy, complicating manufacturing and regulatory review.

Site-Specific Conjugation

Modern ADCs increasingly employ site-specific conjugation for homogeneous products:

• Engineered cysteines (THIOMABs): Introducing additional cysteine residues at specific positions for controlled conjugation
• Enzymatic conjugation: Using enzymes such as sortase A, transglutaminase, or formylglycine-generating enzyme for site-specific attachment
• Non-natural amino acids: Incorporating amino acids with unique chemical handles for selective conjugation
• Glycan conjugation: Attaching payloads to engineered antibody glycans

Site-specific conjugation produces homogeneous ADCs with defined DAR, improved pharmacokinetics, and simplified characterization.

Approved ADCs

As of 2026, the following ADCs have received regulatory approval:

ADC	Brand Name	Target	Payload	Linker	Indication
Gemtuzumab ozogamicin	Mylotarg	CD33	Calicheamicin	Acid-labile	AML
Brentuximab vedotin	Adcetris	CD30	MMAE	Protease-cleavable	Hodgkin lymphoma, ALCL
Ado-trastuzumab emtansine	Kadcyla	HER2	DM1	Non-cleavable	HER2+ breast cancer
Inotuzumab ozogamicin	Besponsa	CD22	Calicheamicin	Acid-labile	ALL
Trastuzumab deruxtecan	Enhertu	HER2	DXd	Protease-cleavable	HER2+ breast cancer, gastric cancer
Sacituzumab govitecan	Trodelvy	TROP-2	SN-38	Acid-labile	Triple-negative breast cancer
Enfortumab vedotin	Padcev	Nectin-4	MMAE	Protease-cleavable	Urothelial cancer
Datopotamab deruxtecan	-	TROP-2	DXd	Protease-cleavable	NSCLC, breast cancer
Disitamab vedotin	Aidixi	HER2	MMAE	Protease-cleavable	Gastric cancer (China)
Tisotumab vedotin	Tivdak	TF	MMAE	Protease-cleavable	Cervical cancer

Toxicity Management

Adverse Effect Profiles

ADC toxicities differ from both traditional chemotherapy and unconjugated antibodies:

• Ocular toxicity: Corneal changes (keratitis, blurred vision) are common with several ADCs, possibly due to payload accumulation in rapidly dividing corneal epithelial cells
• Hematologic toxicity: Neutropenia and thrombocytopenia, particularly with microtubule inhibitor payloads
• Hepatotoxicity: Elevated liver enzymes and, in rare cases, veno-occlusive disease (particularly with calicheamicin-based ADCs)
• Peripheral neuropathy: Common with microtubule-inhibiting payloads, especially MMAE
• Interstitial lung disease (ILD): Particularly associated with trastuzumab deruxtecan; requires vigilant monitoring and prompt management
• Dermatologic toxicity: Rash, alopecia, and palmar-plantar erythrodysesthesia

Management Strategies

• Dose modification: Dose reduction or treatment delay for grade ≥2 toxicities
• Prophylactic measures: Corticosteroid eye drops for ocular toxicity; G-CSF support for neutropenia
• Monitoring protocols: Regular pulmonary function assessment, complete blood counts, and liver function tests
• Patient education: Early reporting of symptoms such as cough, dyspnea, or visual changes

Future Directions

Novel Targets

ADC development is expanding beyond traditional tumor antigens:

• Bispecific ADCs: Targeting two different antigens to improve tumor specificity and overcome resistance
• Immune cell-targeting ADCs: Delivering immunomodulatory payloads to immune cells rather than tumor cells
• Stromal targets: Targeting tumor stroma and vasculature

Novel Payloads

• Novel mechanism payloads: Moving beyond microtubule inhibitors and DNA-damaging agents to include protein degradation-inducing payloads, immune agonists, and molecular glues
• Dual-payload ADCs: Conjugating two different payloads to the same antibody to overcome resistance and target heterogeneous tumors

Beyond Oncology

While ADCs have been developed primarily for oncology, the technology is being explored for:

• Autoimmune diseases: Delivering immunosuppressive agents to specific immune cell populations
• Infectious diseases: Targeting intracellular pathogens with antibiotic payloads
• Fibrotic diseases: Delivering anti-fibrotic agents to activated fibroblasts

Manufacturing Advances

• Improved conjugation technologies for homogeneous products
• Enhanced analytical methods for comprehensive ADC characterization
• Process optimization to reduce manufacturing costs, which remain a significant barrier (see biologics vs small molecules comparison)

Conclusion

Antibody-drug conjugates have established themselves as a transformative therapeutic modality in oncology, demonstrating that the targeted delivery of potent cytotoxic agents can achieve meaningful clinical benefit with manageable toxicity. The continued evolution of ADC technology—through novel targets, innovative linker chemistries, next-generation payloads, and site-specific conjugation—promises to expand the therapeutic index and clinical applicability of these complex molecules. As the field advances, the integration of biomarker-guided patient selection, precision medicine approaches, and rational combination strategies will further enhance the clinical impact of ADCs. For researchers and clinicians seeking detailed ADC information, the CodeDrug database provides comprehensive data on approved and investigational antibody-drug conjugates, while the research tools support ADC design and analysis.